Showing results (81-90 of 194) with videos related to
Sort By:
Pageof 20
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.Plos One|November 12, 2019
Post-treatment Lyme disease symptoms score: Developing a new tool for researchSiu P Turk, Keith Lumbard, Kelly Liepshutz, et al.The Journal of Infectious Diseases|December 23, 2016
Assessment and Optimization of the GeneXpert Diagnostic Platform for Detection of Ebola Virus RNA in Seminal FluidJames Pettitt, Elizabeth Higgs, Mosoka Fallah, et al.Journal of Cardiac Failure|October 30, 2003
A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUSMichael J Domanski, Heidi Krause-Steinrauf, Barry M Massie, et al.Journal of Virology|January 20, 2012
HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopesNicole A Doria-Rose, Mark K Louder, Zhongjia Yang, et al.The Journal of Infectious Diseases|February 26, 2015
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure ProphylaxisOliver Laeyendecker, Andrew D Redd, Martha Nason, et al.Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.Proceedings of the National Academy of Sciences of the United States of America|December 9, 2008
HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cellsMarta Catalfamo, Michele Di Mascio, Zonghui Hu, et al.Nature Communications|June 26, 2020
Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodiesDavid A Garber, Debra R Adams, Patricia Guenthner, et al.Journal of Immunotoxicology|October 3, 2008
Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene insertsRebecca L Sheets, Judith Stein, Robert T Bailer, et al.Pageof 20